Publications by authors named "Johannes Hankowitz"
Background: Life-threatening heparin-induced thrombocytopenia (HIT) is treated with the alternative nonheparin anticoagulants argatroban, lepirudin, or danaparoid. Frequently, the pentasaccharide fondaparinux is used off-label.
Objectives: The authors sought to investigate the safety and efficacy of the different anticoagulants for treating HIT.
With the recent approval of the fourth direct non vitamin K dependent oral anticoagulant (NOAC) edoxaban the range of available NOACs for the treatment of venous thromboembolism (VTE) has expanded. Shortly thereafter, two updated guidelines for the prevention and treatment of VTE have been published. In these NOACs are listed as equal anticoagulants to low-molecular weight heparin (LMWH), or fondaparinux (FDX), and VKA for the initial or maintenance treatment of VTE.
View Article and Find Full Text PDF[Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation].
Herzschrittmacherther Elektrophysiol
September 2016
With the introduction of edoxaban last year in Germany, four nonvitamin K antagonist oral anticoagulants are now available for stroke prevention in patients with nonvalvular atrial fibrillation. These novel oral anticoagulants (NOAC) represent an attractive new option compared to vitamin K antagonists (e.g.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the management of suspected acute heparin-induced thrombocytopenia (HIT) using non-heparin anticoagulants, emphasizing off-label use of fondaparinux.
- The research involved a national registry with 195 patients, focusing on their 4T's HIT-probability scores and treatment outcomes, revealing various complications during heparin therapy.
- Findings indicate a high reliance on immunoassays for diagnosis and significant off-label fondaparinux usage, highlighting the need for further evaluation of its efficacy and safety in treating HIT.